Abstract: Embodiments of secondary batteries having electrode assemblies are provided. A secondary battery can comprise an electrode assembly having a stacked series of layers, the stacked series of layers having an offset between electrode and counter-electrode layers in a unit cell member of the stacked series. A set of constraints can be provided with a primary constraint system with first and second primary growth constraints separated from each other in a longitudinal direction, and connected by at least one primary connecting member, and a secondary constraint system comprises first and second secondary growth constraints separated in a second direction and connected by members of the stacked series of layers. The primary constraint system may at least partially restrain growth of the electrode assembly in the longitudinal direction, and the secondary constraint system may at least partially restrain growth in the second direction that is orthogonal to the longitudinal direction.

Abstract: Techniques are disclosed for usage-tracking of various information security (InfoSec) entities for tenants/organization onboarded on an instant multi-tenant security assurance platform. The InfoSec entities include policies, procedures, controls and evidence tasks. A policy or procedure is enforced by implementing one or more controls, and the collection of one or more evidence tasks proves/verifies the implementation of a control. The InfoSec entities are linked to each other across the platform and accrue a number of benefits for the tenants. These include generating a security questionnaire response (SQR), defining a readiness project and an audit project, sharing InfoSec entities encompassing the various products of a tenant, automating risk assessment, automatic collection of evidence tasks for verifying the implementation and/or operational state/status of various mitigating controls, etc.

Abstract: Secondary batteries and methods of manufacture thereof are provided. A secondary battery can comprise an offset between electrode and counter-electrode layers in a unit cell. Secondary batteries can be prepared by removing a population of negative electrode subunits from a negative electrode sheet, the negative electrode sheet comprising a negative electrode sheet edge margin and at least one negative electrode sheet weakened region that is internal to the negative electrode sheet edge margin, removing a population of separator layer subunits from a separator sheet, and removing a population of positive electrode subunits from a positive electrode sheet, the positive electrode sheet comprising a positive electrode edge margin and at least one positive electrode sheet weakened region that is internal to the positive electrode sheet edge margin, and stacking members of the negative electrode subunit population, the separator layer subunit population and the positive electrode subunit population.

Abstract: Embodiments of secondary batteries having electrode assemblies are provided. A secondary battery can comprise an electrode assembly having a stacked series of layers, the stacked series of layers having an offset between electrode and counter-electrode layers in a unit cell member of the stacked series. A set of constraints can be provided with a primary constraint system with first and second primary growth constraints separated from each other in a longitudinal direction, and connected by at least one primary connecting member, and a secondary constraint system comprises first and second secondary growth constraints separated in a second direction and connected by members of the stacked series of layers. The primary constraint system may at least partially restrain growth of the electrode assembly in the longitudinal direction, and the secondary constraint system may at least partially restrain growth in the second direction that is orthogonal to the longitudinal direction.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: A computer system that includes one or more processors configured to execute a secure sovereign manager that controls remote execution of commands on a sovereign cloud computing platform. The secure sovereign manager is configured to create an escorted session for an unqualified user for invoking commands on the sovereign cloud computing platform. The unqualified user does not have sovereign-trusted credentials that define qualifications required for accessing the sovereign cloud computing platform. The escorted session is asynchronously supervised by a qualified user that has sovereign-trusted credentials. The secure sovereign manager is configured to receive an indication of approval or denial of invocation of a received command. Based on at least receiving an indication of approval, the secure sovereign manager invokes the received command on the sovereign cloud computing platform.

Abstract: A computer system that includes one or more processors configured to execute a secure sovereign manager that controls remote execution of commands on a sovereign cloud computing platform. The secure sovereign manager is configured to create an escorted session for an unqualified user for invoking commands on the sovereign cloud computing platform. The unqualified user does not have sovereign-trusted credentials that define qualifications required for accessing the sovereign cloud computing platform. The escorted session is asynchronously supervised by a qualified user that has sovereign-trusted credentials. The secure sovereign manager is configured to receive an indication of approval or denial of invocation of a received command. Based on at least receiving an indication of approval, the secure sovereign manager invokes the received command on the sovereign cloud computing platform.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: An embodiment firearm accessory mount includes: a main base including: a firearm groove at a bottom of the main base; and a mating groove at a top of the main base, the mating groove extending from a front of the main base to a rear of the main base, a first width of the mating groove decreasing continually in a first direction extending from the front of the main base to the rear of the main base; and an accessory mount including: an accessory groove at a top of the accessory mount; and a mating slide at a bottom of the accessory mount, the mating slide extending from a front of the accessory mount to a rear of the accessory mount, a second width of the mating slide decreasing continually in a second direction extending from the front of the accessory mount to the rear of the accessory mount.

Abstract: An example method includes receiving, at a CPU, a data request from a data requester to search or filter data in a repository. At least a first portion of the data is homomorphically encrypted. The method includes analyzing the stored data without decrypting the homomorphically encrypted data to determine an aggregated subset of data relevant to the data request. The analyzing includes: dispatching, from the CPU, a command to a hardware accelerator to execute an operation on the homomorphically encrypted data; executing, at the hardware accelerator, the operation on the homomorphically encrypted data; and receiving, at the CPU, an output of the execution of the operation by the hardware accelerator, where the aggregated subset of data is based on the output. The method includes providing data request results that include or are derived from the aggregated subset of data to the data requester.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present disclosure generally relates to the secure exchange of data. In some implementations, an example method involves receiving data from a number of independent data sources. The method also includes storing the data in a central repository where at least a first portion of the data is homomorphically encrypted, receiving a data request from a data requester, and analyzing the stored data without decrypting the homomorphically encrypted data to determine an aggregated subset of data relevant to the data request. The aggregated subset of data may include at least some of the homomorphically encrypted data. The method also includes providing data request results that include or are derived from the aggregated subset of data to the data requester.

Abstract: A method and apparatus of re-railing a rail car involving the use of one or more extendable arms carried by each individual rail car is provided. The extendable arms may be operable to extend outward from the rail car and then lower an extendable foot to contact the ground, thus allowing the car to be raised into position back over the rails of the associated train tracks utilizing these extendable arms. Since the arms are compact and carried by the rail car themselves, there is no time lost while lifting equipment is brought in and cars may be quickly and efficiently re-railed to minimize the overall time loss of the associated train tracks.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.

Abstract: A computer system that includes one or more processors configured to execute a secure sovereign manager that controls remote execution of commands on a sovereign cloud computing platform. The secure sovereign manager is configured to create an escorted session for an unqualified user for invoking commands on the sovereign cloud computing platform. The unqualified user does not have sovereign-trusted credentials that define qualifications required for accessing the sovereign cloud computing platform. The escorted session is asynchronously supervised by a qualified user that has sovereign-trusted credentials. The secure sovereign manager is configured to receive an indication of approval or denial of invocation of a received command. Based on at least receiving an indication of approval, the secure sovereign manager invokes the received command on the sovereign cloud computing platform.

Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or pharmaceutically acceptable salts thereof wherein R, R1, R2, R3, R4, R5, R6, R7, and R8, are as defined herein. The disclosure also relates to methods of making and using compounds of Formula (I) or pharmaceutically acceptable salts thereof.